{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-044318","form_type":"8-K","ticker":"CORT","cik":"0001088856","company_name":"CORCEPT THERAPEUTICS INC","filed_at":"2024-10-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:07.630012+00:00","generated_at":"2026-05-30T07:59:05.053583+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Corcept Q3 revenue $182.5M (+48% YoY); guides FY2024 to $675-700M; positive GRADIENT results","bullets":["Q3 revenue $182.5M (+48% YoY); diluted EPS $0.41 vs $0.28; net income $47.2M.","FY2024 revenue guidance raised to $675-700M from $640-670M; strong Korlym prescriber and patient growth.","Cash and investments $547.6M; repurchased 870K shares for $23.4M in Q3.","Phase 3 GRADIENT in Cushing's syndrome: significant improvements in BP, glucose, weight vs placebo; no hypokalemia or endometrial hypertrophy.","NDA for relacorilant in Cushing's to be submitted this quarter; ROSELLA (ovarian cancer) and DAZALS (ALS) data expected by year-end."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-044318","json":"https://secwatch.observer/filing/0001628280-24-044318.json","markdown":"https://secwatch.observer/filing/0001628280-24-044318.md","text":"https://secwatch.observer/filing/0001628280-24-044318.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1088856/000162828024044318/0001628280-24-044318-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1088856/000162828024044318/cort-20241030.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T07:59:05.053583+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}